MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
17.78
-0.05
-0.28%
Opening 11:50 10/06 EDT
OPEN
17.99
PREV CLOSE
17.83
HIGH
18.19
LOW
16.85
VOLUME
398.91K
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
12.99
MARKET CAP
1.59B
P/E (TTM)
-7.0508
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SNDX last week (0928-1002)?
Weekly Report · 1d ago
Syndax Pharmaceuticals (SNDX) Looks Undervalued On Paper, Is It Still A Bargain?
Simply Wall St · 4d ago
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Pyxis Oncology (PYXS)
TipRanks · 5d ago
Axatilimab’s Emerging IPF and cGVHD Profile Supports Buy Rating on SNDX, With Price Target Unchanged at $57
TipRanks · 09/29 10:25
Weekly Report: what happened at SNDX last week (0921-0925)?
Weekly Report · 09/28 09:48
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
Seeking Alpha · 09/28 09:22
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts
Seeking Alpha · 09/25 16:28
Syndax Pharmaceuticals (SNDX) Stock Looks Fully Valued After Its 21% Gain
Simply Wall St · 09/23 09:28
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.